Evidence map›Paper›PMID 42581433›Full record

ArticleJournal of cellular and molecular medicine2026

A Novel Mechanism of Tumour Communication: Malignant Extracellular Vesicles-Induced Aggressiveness in Benign Cells and Melatonin-Driven Reversal.

Barbara Maria Frigieri, Guilherme Silva Bruno Barbosa, Adriana Alonso Novais, Caroline Patini de Rezende, Fausto Almeida, Vinicius Augusto Simão, Mari Cleide Sogayar, Luiz Gustavo de Almeida Chuffa, Russel J Reiter, Debora Aparecida Pires de Campos Zuccari

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Barbara Maria FrigieriCancer Molecular Research Laboratory (CMRL), Faculdade de Medicina de São José do Rio Preto-FAMERP, São José do Rio Preto, Brazil.ORCID 0000-0002-6275-3273
Guilherme Silva Bruno BarbosaCancer Molecular Research Laboratory (CMRL), Faculdade de Medicina de São José do Rio Preto-FAMERP, São José do Rio Preto, Brazil.ORCID 0000-0001-7880-8374
Adriana Alonso NovaisCancer Molecular Research Laboratory (CMRL), Faculdade de Medicina de São José do Rio Preto-FAMERP, São José do Rio Preto, Brazil.ORCID 0000-0002-3399-0202
Caroline Patini de RezendeCancer Molecular Research Laboratory (CMRL), Faculdade de Medicina de São José do Rio Preto-FAMERP, São José do Rio Preto, Brazil.ORCID 0000-0001-8263-6958
Fausto AlmeidaDepartment of Immunology and Biochemistry, Ribeirão Preto Medical School-USP, Cidade Universitária, Ribeirão Preto, Brazil.ORCID 0000-0002-3782-3698
Vinicius Augusto SimãoDepartment of Structural and Functional Biology, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, Brazil.ORCID 0000-0002-3915-2795
Mari Cleide SogayarNucel Group for Cellular and Molecular Therapy, São Paulo Medical School-USP, São Paulo, Brazil.ORCID 0000-0003-4805-4609
Luiz Gustavo de Almeida ChuffaDepartment of Structural and Functional Biology, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, Brazil.ORCID 0000-0002-0199-3396
Russel J ReiterDepartment of Cell Systems and Anatomy, Joe R and Teresa Lozano Long School of Medicine, UT Health San Antonio, San Antonio, Texas, USA.ORCID 0000-0001-6763-4225
Debora Aparecida Pires de Campos ZuccariCancer Molecular Research Laboratory (CMRL), Faculdade de Medicina de São José do Rio Preto-FAMERP, São José do Rio Preto, Brazil.ORCID 0000-0002-0146-9041

Funding

Conselho Nacional de Desevolvimento Cientfico e Tecnologico (CNPQ) 306117/2023-1Conselho Nacional de Desevolvimento Cientfico e Tecnologico (CNPQ) 307288/2022-6Fundação de Amparo à Pesquisa do Estado de São Paulo 2016/05311-2Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/12970-8the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) 88887.707044/2022-00
6 · The paper itself

Abstract

Extracellular vesicles (EVs/EV) are key mediators of intercellular communication and influence proliferation, migration, and metabolic reprogramming. In breast cancer, EVs released by malignant cells carry bioactive molecules capable of altering the behaviour of surrounding cells. However, it remains uncertain whether these vesicles can directly induce a more aggressive phenotype in benign mammary cells. Melatonin, known for its oncostatic properties, regulates proliferation, metabolism, and signalling pathways associated with tumour progression and may modulate EV-mediated intercellular communication. This study evaluated whether EVs derived from four breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-453 and HCC70), treated or not with melatonin, can modify the phenotype of benign MCF10A cells. EVs were isolated from conditioned media and co-cultured with benign cells. Assays of proliferation, viability, colony formation, migration, lactate production and immunofluorescence were performed to assess EV-mediated effects. EVs derived from malignant cells promoted a more aggressive phenotype in benign cells, as evidenced by increased proliferation, migration, and phenotypic remodelling. In contrast, EVs derived from melatonin-treated malignant cells were associated with reduced lactate production and attenuation of pro-tumoural features. Overall, these findings demonstrate that tumour-derived EVs can induce aggressive traits in benign mammary cells and suggest that melatonin exposure in donor cells modulates EV-mediated effects, attenuating their pro-tumoural influence.

Indexed as

Breast NeoplasmsCell CommunicationExtracellular VesiclesMelatoninCell Line, TumorCell MovementCell ProliferationCulture Media, ConditionedFemaleHumansMCF-7 CellsMDA-MB-231 CellsCulture Media, ConditionedMelatoninbreast cancerextracellular vesiclesmelatoninphenotypic remodellingtumour microenvironment

Identifiers

PMID42581433
PMCPMC13462189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.